Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.

Collegium antropologicum - 1 Sept 2012

Duletić Antica Nacinović, Dekanić Andrea, Hadzisejdić Ita, Kusen Ivona, Matusan-Ilijas Koviljka, Grohovac Dragana, Grahovac Blazenka, Jonjić Nives

Abstract excerpt

The aim of this study is to investigate the differences of clinical and laboratory parameters between patients with JAK2-V617F positive myeloproliferative neoplasms (MPNs) and JAK2 wild type MPNs. DNA was isolated from peripheral blood granulocytes of 106 patients treated at Rijeka University Hospital Center: 41 with polycythemia vera (PV), 43 with essential thrombocythemia (ET), 9 with primary myelofibrosis...

Topics

Join the communities discussing this publication.

Genetic Predisposition to Disease
Janus Kinase 2
Myeloproliferative Disorders
Point Mutation
Polycythemia Vera

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Primary Myelofibrosis

Thrombocythemia, Essential

Source

Identifiers

PMID: 23213945

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.PMID 23213945Read ↗

Myeloproliferative neoplasms and JAK2 mutations.Semantic proximity Read ↗

JAK2 V617F Mutational Burden and Clinical Findings Relationship in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm.Semantic proximity Read ↗

Genetic basis of MPN: Beyond JAK2-V617F.Semantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasmsSemantic proximity Read ↗

Clinical implications of JAK2 mutations in myeloproliferative disorders.Semantic proximity Read ↗

Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.Semantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasms.Semantic proximity Read ↗

Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis.Semantic proximity Read ↗

Guidelines for the management of myeloproliferative neoplasms.Semantic proximity Read ↗

Molecular Characterization of Polycythemia VeraSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.